Item 8.01. Other Events.



On January 20, 2022, BeiGene, Ltd. ("the Company") issued a press release
announcing that the Center for Drug Evaluation (CDE) of the China National
Medical Products Administration (NMPA) has accepted a supplemental new drug
application (sNDA) for BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) as a
treatment for adult patients with Waldenström's macroglobulinemia (WM). A copy
of this press release is attached hereto as Exhibit 99.1, and is incorporated
herein by reference.

On January 24, 2022, the Company issued a press release announcing positive
findings from the global Phase 3 RATIONALE 305 trial of tislelizumab versus
placebo in combination with chemotherapy as a first-line treatment for patients
with locally advanced, unresectable or metastatic gastric or gastroesophageal
junction (G/GEJ) adenocarcinoma. At the interim analysis, tislelizumab in
combination with chemotherapy met the primary endpoint of overall survival (OS)
in patients with PD-L1 expression, with additional follow-up needed to confirm
OS benefits in the intention-to-treat (ITT) population. The safety profile of
tislelizumab was consistent with that observed in previous trials, with no new
safety signals identified with the addition of chemotherapy. A copy of this
press release is attached hereto as Exhibit 99.2, and is incorporated herein by
reference.


Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Announces

Acceptance of a Supplemental New Drug


                          Application in China for BRUKINSA (zanubrutinib) in Waldenström's
                          Macroglobulinemia," issued by BeiGene, Ltd. on January 20, 2022.

       99.2               Press Release titled "BeiGene Announces Positive

Findings from Phase 3 Trial of


                          Tislelizumab in Combination with Chemotherapy in

First-Line Gastric or


                          Gastroesophageal Junction Cancer," issued by

BeiGene, Ltd. on January 24, 2022.


       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses